Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $269.50, but opened at $258.1201. Genmab A/S shares last traded at $258.1201, with a volume of 3 shares.
Genmab A/S Trading Down 4.2%
The company’s 50 day moving average price is $270.06 and its 200 day moving average price is $298.26. The company has a market cap of $15.89 billion, a price-to-earnings ratio of 19.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by ($2.55). The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.
Genmab A/S Company Profile
Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.
See Also
- Five stocks we like better than Genmab A/S
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
